COVID-19 Update


Project Line:
New at CADTH

CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.

Our COVID-19 Evidence Portal contains the latest COVID-19 information from CADTH and other respected organizations. Content is updated daily to reflect the rapidly changing and increasing international scientific evidence related to this disease.

The following is a summary of the most recent information posted to our COVID-19 portal.


Tocilizumab and Sarilumab: Evidence Review and Appraisal

  • Tocilizumab and sarilumab are classified as humanized monoclonal antibodies against the interleukin-6 receptor and are used in rheumatology.
  • This review on tocilizumab and sarilumab for their potential use in managing COVID-19 is current as of February 25, 2021.

Casirivimab-Imdevimab for COVID-19: Evidence Review and Appraisal

  • REGN-COV2 combines 2 virus-neutralizing monoclonal antibodies that are used against SARS-CoV-2: casirivimab and imdevimab (CAS-IMD).
  • This review (current as of February 23, 2021) evaluated a published interim analysis of a randomized controlled trial of 2 different doses of CAS-IMD in 275 ambulatory adult patients with confirmed SARS-CoV-2 infection.

COVID-19 News

Visit our COVID-19 news page to stay on top of all the emerging information we are monitoring and updating. Here’s the latest news:

  • Monoclonal Antibody VIR-7831
    On March 10, 2021, a press release was issued describing the interim results of a trial of the monoclonal antibody VIR-7831 as monotherapy for the early treatment of COVID-19 in non-hospitalized patients.

CADTH Literature Searching Tools

To help conduct your COVID-19–related literature searches, see our COVID-19 Search Strings and our COVID-19 Grey Literature Resources.

Additional Resources

CADTH is pleased to showcase additional COVID-19 resources from our partner organizations and the Canadian federal, provincial, and territorial governments’ health jurisdictions:

  • Pan-Canadian Health Organizations
  • Federal, Provincial, and Territorial Information

Other CADTH COVID-19 News

Ensuring High-Value Health Care After the Pandemic

  • CADTH is partnering with Choosing Wisely Canada to identify actions that could lead to better post-pandemic care for Canadians. The organizations are developing recommendations for reducing low-value care that, if implemented, could make more resources available to deliver the priority services that are most beneficial to patients.
  • As a next step, CADTH will convene a panel of Canadian clinician, patient, and policy experts to review the shortlist and develop final recommendations for clinicians and senior policy decision-makers.
  • The results will be presented at Choosing Wisely Canada’s National Meeting in May 2021 and will be published in CADTH’s Canadian Journal of Health Technologies.
  • For more information, contact [email protected] or [email protected].


Canadian ministries and departments of health, publicly funded organizations responsible for health service delivery, and clinical society stakeholders are encouraged to submit a request or contact their CADTH Liaison Officer. We’re here to help.

The CADTH Weekly COVID-19 Update is intended to keep you informed about the latest information posted on the CADTH COVID-19 portal.